Drug intelligence / Profile preview

AI-102

Development stage: Unknown
Lead developer: AI Therapeutics

Overview

AI-102 is a drug code name for which specific detailed information is not readily available in public databases. While it appears in drug monograph listings, such as on MedPath, no further details regarding its mechanism of action, therapeutic indications, or development status are provided under this exact designation. The name 'AI-102' is highly non-specific, as numerous other drug candidates and even non-pharmaceutical entities (like a Microsoft Azure certification) utilize similar 'X-102' naming conventions, leading to significant ambiguity. Therefore, a comprehensive profile for a drug specifically identified as AI-102 cannot be constructed from available public information.

Targets

KLF (Krüppel-like factor family)SP1 (Transcription factor Sp1)

Beyond the preview

Go deeper on AI-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI-102.

Explore the full profile